Kidder Williams has another 6 months to either sell the company,...

Kidder Williams has another 6 months to either sell the company, or find a cornerstone investor.

In that time, aside from being funded until end first quarter 2024, they can demonstrate:

1. Sales
2. New RCT studies for extension of label started in Europe
3. Germany hopefully approved to start and (if all planets align maybe)
4. FDA approval for cholangio

But its a binary outcome, like lots of things in biomedtech.

If they do a deal, share price explodes. If they don't, well, the opposite.

I think the major holders understand this so I don't think the overhang, as you describe it, is as big as you think. They, like me, will wait for a deal. We all decided that the potential value of the company in a sale would be multiples of the current (or last raise) market cap. Only way to find out is to wait.

Keep calm and carry on.